SCHEMBL22182084

SCHEMBL22182084

CSc1cc(-c2ccc(NCCCN3C(=O)c4cccc5cccc(c45)C3=O)cc2)ccc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIRT1 Q96EB6 3/20 0.47
▸ HEXA P06865 7/20 0.47
▸ HEXB P07686 7/20 0.47
▸ OGA O60502 1/20 0.44
▸ POLB P06746 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ NR1I2 O75469 1/20 0.43
▸ AHR P35869 1/20 0.43
▸ RAD52 P43351 1/20 0.43
▸ RCE1 Q9Y256 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ CYP3A4 P08684 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ HDAC3 O15379 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22181861 0.88 SIRT1 (0.53) SIRT1HEXAHEXBOGAPOLB
SCHEMBL22182117 0.87 SIRT1 (0.50) SIRT1HEXAHEXBOGAPOLB
SCHEMBL22182085 0.83 SIRT1 (0.47) SIRT1HEXAHEXBOGAPOLB
SCHEMBL22181894 0.83 SIRT1 (0.53) SIRT1HEXAHEXBOGAPOLB
SCHEMBL22181892 0.83 SIRT1 (0.51) SIRT1HEXAHEXBOGAPOLB
SCHEMBL22181854 0.83 SIRT1 (0.57) SIRT1HEXAHEXBOGAPOLB
SCHEMBL22181889 0.82 LPAR2 (0.52) SIRT1HEXAHEXBALDH1A1HPGD
SCHEMBL22182115 0.82 SIRT1 (0.49) SIRT1HEXAHEXBOGAPOLB
SCHEMBL22181859 0.81 HEXA (0.63) SIRT1HEXAHEXBOGAPOLB
SCHEMBL22181917 0.81 SIRT1 (0.57) SIRT1HEXAHEXBOGAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020139291-A1 NAPHTHALIMIDE DERIVATIVES AS ANTI-PARASITIC AGENTS FOR THE TREATMENT OF LEISHMANIASIS AS WELL AS VIRAL, BACTERIAL AND NEOPLASTIC DISEASES ISTANBUL MEDIPOL UNIVERSITESI (TR) 2020-07-02 — — WO disclosed
Send feedback